Takashi Ono, Ph.D.
President and Chief Executive Officer
- Joined as Chief Operating Officer in 2018 and assumed as CEO in March 2019
- Project Manager, ITOCHU Corporation in 2009
- (concurrently VP Business Development, Solasia Pharma K. K.)
- General Manager of Business Development, Sosei Co., Ltd.in 2002
Chief Financial Officer
- Joined as CFO in October 2020
- VP Administration, Solasia Pharma K. K.in 2014
- Board member, au Payment Corporation (formerly Webmoney Corporation) in 2009
- Executive Officer, Faith, Inc. in 2005
Yusuke Yagi, Ph.D.
Chief Technical Officer
- Founder of EditForce, Inc. and assumed as CTO in March 2019
- Director of Research & Development from 2016
- Specialist of PPR protein, establishing the basis of PPR Platform Technology at Kyushu University from 2011
Osamu Nakanishi, Ph.D.
Chief Scientific Officer
- Joined as Director of Research & Development in March 2020 and assumed as CSO in August 2020
- Head of West Japan Office, Department of drug discovery, Japan Agency for Medical Research and Development(AMED) in 2015
- Head of West Japan Office, Center for drug discovery, National Institutes of Biomedical Innovation, Health and Nutrition (formarly National Institute of Biomedical Innovation) in 2013 after working for several pharmaceutical companies
Partner and Board Director, The University of Tokyo Edge Capital Partners Co., Ltd.
Vice President, ITOCHU Technology Ventures, Inc.
Representative Partner, TM Partners LLC
Manager, Regional Economy Vitalization Corporation of Japan
Certified Public Accountant
Advisor, Clinical and Medical Sciences, Newton Biocapital Partners
President, Japan Securities Research Institute
Audit & Supervisory Board Member
Managing Partner, CEO and President, The University of Tokyo Edge Capital Partners Co., Ltd.
Chief Lawyer, Ogata Law Firm
Scientific Advisory Board
Prof., School of Agriculture, Graduate School of Kyushu Univ.
Prof., Graduate school of Integrated Sciences for Life, Hiroshima Univ.
Former Vice Director,Hokkaido University Hospital, Clinical Research and Medical Innovation Center.
Chief Clinical and Regulatory Officer of Bone Therapeutics Independent Director of Ogeda and Pluriomics